A 23 year old male's 9-month progress with 1mg/day of finasteride, which has been life changing and resulted in a significant improvement in hair thickness.
A user's progress with treating hair loss using finasteride, minoxidil and microneedling over the course of 7 months. Other comments suggested additional treatments such as toppik to help hide it in the meantime.
A user's experience of using finasteride to treat hair loss, including details about shedding and side effects; their regimen; and the advice given by others about diet, sport, smoking, and topical treatments.
This conversation details the impressive one year progress of a user's hair loss treatment, which included taking daily doses of dutasteride and minoxidil. Other users shared their own experiences with similar treatments, such as not having any shedding when starting, or having an oily scalp that improved significantly.
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.
Minoxidil increases hair count despite high prolactin being linked to hair loss. Blocking DHT is effective, but not always necessary; HMI-115 is a promising treatment for androgenetic alopecia.
A user's progress in using medications such as finasteride and minoxidil, along with keto shampoo and microneedling, to treat their hair loss. Replies suggested that the user was seeing positive results quickly, but noted the heavy treatments used may cause extra shedding.
Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.